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PURPOSE. The purpose of this study was to compare two interventions for depression, problem
solving treatment (PST) and referral to the patient’s physician, with a waiting-list control
group in people with sight loss and depressive symptoms.
METHODS. This was an assessor-masked, exploratory, multicenter, randomized clinical trial,
with concurrent economic analysis. Of 1008 consecutive attendees at 14 low-vision
rehabilitation centers in Britain, 43% (n ¼ 430) screened positive for depressive symptoms
on the Geriatric Depression Scale and 85 of these attendees participated in the trial. Eligible
participants were randomized in the ratio 1:1:1 to PST, referral to their physician, or a waiting-
list control arm. PST is a manualized talking intervention delivered by a trained therapist who
teaches people over six to eight sessions to implement a seven-step method for solving their
problems. Referral to the physician involved sending a referral letter to the person’s
physician, encouraging him or her to consider treatment according to the stepped care
protocol recommended by the U.K.’s National Institute of Health and Care Excellence. The
primary outcome was change in depressive symptoms (6 months after baseline) as
determined by the Beck Depression Inventory.
RESULTS. At 6 months, Beck Depression Inventory scores reduced by 1.05 (SD 8.85), 2.11 (SD
7.60), and 2.68 (SD 7.93) in the waiting-list control, referral, and PST arms, respectively. The
cost per patient of the PST intervention was £1176 in Wales and £1296 in London.
CONCLUSIONS. Depressive symptoms improved most in the PST group and least in the control
group. However, the change was small and the uncertainty of the measurements relatively
large.
Keywords: low vision, depression, clinical trial, mental health, intervention
A growing body of evidence suggests that low vision isassociated with depression. Results from several studies in
North America suggest that the prevalence of depression and
depressive symptoms in those accessing visual rehabilitation
centers ranges from 22% to 38%.1–4 Untreated depression has a
profound negative impact on quality of life and reduces life
expectancy.5–7 What is less clear, however, is how to treat the
depressive symptoms in this vulnerable group.
In otherwise healthy adults, about 50% of those who receive
psychological treatments or antidepressants recover fully.8,9
However, the effects of depression treatment in people with
chronic health conditions are somewhat less clear. For
example, a recent meta-analysis of psychological interventions
for depression in people with coronary heart disease concluded
that although psychological treatments work, the effects are
only small (typical effect size 0.3).10
A myriad of psychological interventions have been devel-
oped for depression, but perhaps the best known and most
useful approaches in the context of those with chronic health
problems are cognitive behavioral therapy (CBT), behavioral
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activation (BA), and problem-solving treatment (PST).10–13
Antidepressant drugs are not recommended for the treatment
of subthreshold depressive symptoms or mild depression in
people with chronic health problems.7 However, they may be
of value in those with long-standing subthreshold symptoms or
a past history of moderate or severe depression.7
In those with sight problems and depression, there is some
evidence that psychological treatments for depression work.
For example, in a clinical trial comparing PST to usual care in
people with age-related macular degeneration (AMD), PST
halved the incidence of a depressive disorder at 2 months,
although the effect had reduced by 6 months.14 Recently, the
Low Vision Depression Prevention Trial, which studied AMD
patients with subthreshold depressive symptoms, showed that
BA combined with occupational therapy halved the incidence
of depressive disorders at 4 months.15
In the United States, access to mental health care services
has been improved by the Affordable Care Act and expansion
of Medicaid, particularly for those most in need.16,17 In Britain,
mental health care is provided by the National Health Service
(NHS) and accessed via the patient’s physician. Within the
NHS, the treatment of people with chronic health problems
and depressive symptoms is supposed to adhere to the detailed
guidelines published by the National Institute for Health and
Care Excellence (NICE).7
To obtain data on the effectiveness of a manualized PST
intervention and a pragmatic referral to the physician to invoke
the NHS’s stepped care approach to depression treatment, we
established the Depression in Visual Impairment Trial (DEP-
VIT).
DEPVIT sought to establish the prevalence of significant
depressive symptoms in people attending visual rehabilitation
centers in Britain and undertake an exploratory trial to find out
if PST or physician referral were effective at reducing
depression in people with impaired vision and significant
depressive symptoms.
METHODS
The methods for DEPVIT have been previously described in
detail.18 In brief, the study was a multicenter, individually
randomized, parallel group, exploratory clinical trial. Two
interventions, PST and physician referral, were evaluated
alongside a waiting-list control. All participants had a follow-
up low-vision appointment 6 weeks after the initial low-vision
assessment.
Eligible participants were adults (aged 18 and older)
attending participating low-vision centers (two hospitals in
London and 12 primary care clinics in South Wales) who
scored ‡ 6 on the Geriatric Depression Scale (GDS-15).19 To
ensure the applicability of the results to the target population,
exclusion criteria were kept to a minimum. We excluded those
who (1) had a low-vision assessment within the previous 12
months, (2) were referred to the clinic in error, (3) were
already receiving depression treatment, (4) were unable to
understand English, (5) were unable to use the telephone as a
result of poor hearing, (6) had a severe medical illness that
would preclude participation, (7) reported suicidal ideation,
(8) were outside the catchment area, or (9) screened positive
for significant cognitive/memory problems. The trial followed
the tenets of the Declaration of Helsinki and was approved by
the NHS National Research Ethics Service (11/WA/0014) and
an independent trial steering committee provided study
oversight. The trial was registered prior to recruitment of the
first participant (ISRCTN registry no. 46824140).
The PST implemented in this trial was a brief manualized
cognitive behavioral therapy based on that used by Rovner et
al.14 Trained psychological therapists worked with participants
on an individual basis in their own home or at one of the
research centers to teach them a seven-step method for
approaching and solving their problems. The only differences
between the intervention studied here and that in the original
publication were that the intervention also included large-print
self-help materials on depression and a list of vision-related
organizations. The optometrists providing the low-vision
assessment also shared the patient’s treatment plan with the
therapist via a brief report so that the therapist could help the
patient implement the optometrist’s recommendations via the
PST framework if these were problems that the participant
wanted to address.
To ensure standardization, all three therapists delivering
PST undertook rigorous training and certification before seeing
trial participants. All PST sessions were recorded and a random
sample was reviewed for fidelity purposes.
The referral condition consisted of a standardized letter
(letter 1) sent to the participant’s physician within 2 weeks of
randomization. It informed the physician that their patient had
screened positive for significant depressive symptoms and
asked them to offer treatment according to NICE guidelines.7
The letter was sent by the research team but appeared to come
from the participant’s optometrist. This strategy was used to
mask the fact that the participant was in a research study,
which may have altered the physicians’ behavior. Physicians
were informed about their patients’ participation in this trial 6
months after randomization and asked for information about
any depression treatments offered to the patient during this
period. This was a pragmatic intervention that aimed to
determine the impact of a typical referral, not specifically the
stepped care approach to depression treatment recommended
by the NICE guidelines. The recommended stepped care
approach provides a framework in which to provide services
where the least intrusive, most effective intervention is
provided first. If patients do not respond to the intervention
offered initially, the treatment is stepped up to the next level.
Participants in the waiting-list control arm received no
intervention other than the 6-week follow-up low-vision
assessment.
Any participant who reported severe symptoms (a Beck
Depression Inventory [BDI-II] score of 29 or more) at baseline
or follow-up was referred to their physician for a medication
review using a standardized medication referral letter (letter 2).
The primary outcome was change in depressive symptoms
from baseline to 6 months as measured by the BDI-II.
Secondary outcomes included (1) change in BDI-II baseline
to 3 months and 3 to 6 months; (2) change in visual disability
since baseline interview, as measured by the seven-item
National Eye Institute Visual Function Questionnaire (NEI
VFQ); (3) change in near-visual function as measured using the
near-vision subscale of the Visual Function Questionnaire
(VFQ-48); (4) change in generic health-related quality-of-life
as measured by the EuroQol five dimensions questionnaire
(EQ-5D); and (5) the proportion of participants screening
positive for depression at 6 months using GDS-15.
The randomization sequence was created by the senior data
manager using permuted blocks of varying sizes and was
concealed from the optometrists enrolling participants and the
researchers who obtained the outcomes via telephone
interview. The chief investigator (CI) consulted the allocation
sequence and assigned participants to the next available
allocation.
As a result of the nature of the interventions, participants
were aware of their treatment assignment. The therapists were
aware which participants were assigned to PST; the GPs were
unaware that the participant was in a trial so as not to bias their
actions, and the optometrists were masked to treatment
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assignment but may have been unmasked through discussions
with the participant, although this was actively discouraged.
Outcome assessors were masked and reminded participants at
the beginning of each outcome assessment not to discuss
allocation. All masking violations were recorded and the
assessors were asked to guess each participant’s allocation
before the 6-month interview.
DEPVIT included a concurrent health economic analysis to
determine the cost of the intervention and the overall health
and social care service use costs of participants in the trial.
Measurement and analysis of costs was undertaken from a
multiagency public-sector perspective. Local authority and
NHS service use costs were collected at baseline and 6 months
using the Client Service Receipt Inventory.20 Service use costs
were determined using published national unit costs.21,22 All
costs are reported in £ Sterling for 2013. Mean differences in
cost per patient were calculated for the different types of
service use, and 95% confidence intervals were estimated using
nonparametric bootstrapping methods, run on 5000 iterations.
Service use and related costs for both the intervention and
control arms were collected using the Client Service Receipt
Inventory. Intervention costs for the PST intervention were
collected using cost diaries completed by the therapists. Using
employer data, therapist salary for South Wales was costed at
£39 per hour (including on-costs and overheads) and estimated
to be £49 per hour for London. Mileage was calculated at £0.67
per mile.21 Because of the more rural nature of South Wales,
average mileage per session was reduced by 25% for London.
A statistical analysis plan was developed before the study
started, and a dedicated Microsoft Access database (Microsoft
Corp., Redmond, WA, USA) was constructed. Trial data was
double entered, and all data queries were resolved.
At the outset there were no data on people with sight loss
and significant depressive symptoms on which to power the
clinical trial component of the study, and hence DEPVITwas an
exploratory study. However, working on the assumption that
participants with a mean BDI-II score of 30 (SD 10.5) would
enter the trial and that 60 would provide outcome data at the 6-
month outcome point, the study had 83% power to detect a
moderately large clinically important 10-point reduction in
depressive symptoms at the 5%, two-sided significance level.
The trial analysis was undertaken on an intent-to-treat basis
based on an available case analysis.
The GDS-15, BDI-II, and EQ-5D surveys were scored
traditionally to ensure that the scores would be comparable
with other studies using these measures. The seven-item NEI
VFQ and near-vision subscales of the VFQ 48 were scored
using Rasch analysis implemented with Winsteps version
3.58.1 (Linacre, Chicago, IL, USA).
Baseline characteristics were summarized using means and
standard deviations for continuous (Gaussian) variables and
medians with interquartile ranges for non-Gaussian continuous
variables. Categorical variables were summarized as numbers
and percentages. Although the study was not powered to
detect significant differences, we provide 95% confidence
intervals with treatment effect estimates.23–25
RESULTS
In total, 1008 consecutive patients were screened for eligibility.
Of these, 430 (43%, 95% CI 40%–46%) screened positive for
significant depressive symptoms (GDS-15 ‡6). Of those who
screened positive, 75% were not receiving any treatment for
their depressed mood.
A total of 85 people with significant depressive symptoms
took part in the clinical trial. Figure 1 depicts the CONSORT
flow diagram and identifies the reasons for excluding people.
Table 1 describes the demographic characteristics by
treatment assignment.
Table 2 shows the primary and secondary outcomes by
treatment group. At 6 months, depressive symptoms had
reduced in all three arms. In the waiting-list control arm,
depressive symptoms were reduced by1.05 (95% CI4.33 to
2.23), in the referral arm by2.11 (95% CI4.98 to 0.76), and
in the PST arm by2.68 (95% CI6.00 to 0.63). In all cases, the
95% CI spanned zero, suggesting that change was not
significant at the 5% level.
Post hoc analyses suggest that depressive symptoms
reduced most in those with moderate to severe depressive
symptoms at baseline, that is, a BDI-II > 20. Specifically, in the
waiting-list control, referral, and PST arms, depressive symp-
toms reduced by 2.4, 5.0, and 6.1, respectively, in those
with moderate to severe depression at baseline, and by only
0.3, 2.3, and0.3, respectively, in those with mild or minimal
symptoms at baseline.
At 6 months, the proportion of people still screening
positive for depression according to the GDS-15 had decreased
to 33.3% (95% CI 15.5–51.1), 38.5% (95% CI 19.8–57.2), and
40.9% (95% CI 20.4–61.5) of those in the waiting-list, referral,
and PST arms, respectively.
Table 3 summarizes the action taken by physicians in
response to the referral letters. Letter 1 was for those in the
referral arm. Letter 2 was used to refer all those who had
severe depressive symptoms (BDI-II >29). Of the physicians
who responded (32 of 36), approximately 65% indicated that
they had at least met the patient, and 25% of patients were
offered antidepressants.
On average, South Wales participants received 6.15 PST
sessions (SD 1.21), lasting an average of 1.37 hours (SD 0.41).
Allowing for travel time, the total estimated therapist time was
3.48 hours per session (SD 1.12), giving an average cost per
session of £196 in Wales and £216 for London.
Table 4 summarizes the health and social care service use
costs in each study group for 6 months. The total health and
social care costs, excluding the cost of the interventions,
incurred by those in the waiting-list, referral, and PST arms of
the trial during the 6-month study period were £1444 (SD
£1941), £1362 (SD £1842), and £962 (SD £1051), respectively.
Of the PST recordings, 16% were randomly selected and
reviewed by D.S. using the PST Therapist Adherence and
Competence Scale to ensure fidelity of the intervention.26 The
therapist in Wales received an average score of 4/5, indicating
that the sessions delivered were rated as good. The first
therapist in London conducted only four sessions and was not
reviewed. The second therapist received an average rating of
3.3/5, indicating that the sessions were satisfactory to good.
The researchers were inadvertently unmasked by com-
ments made by participants during 6.8% of interviews, and the
researcher guessed the allocation arm correctly in another
41.9% of cases, that is, only a little higher than by chance alone.
Participants in the waiting-list control group were asked to
refrain from consulting their physician for depression until
after the 6-month interview. Despite this, two participants, one
in Wales and one in London, received depression treatment
from their physicians by 6 months.
Two adverse events were reported, and one was considered
to be related to their prescribed treatment: the participant
experienced dizziness and fell after taking newly prescribed
antidepressant medication. Ten serious adverse events were
reported during the trial, but none were related to the trial.
One participant in the control group reported suicidal
ideation during the 3-month outcome assessment. As per
protocol, he was withdrawn from the trial and urgently
referred to his physician.
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DISCUSSION
Those randomized to receive PST experienced the greatest
reduction in depressive symptoms, and those in the waiting list
the least, but the results were not compelling. The study
suggests that neither active intervention would reduce
depression by the minimal clinically important difference,
although both did appear better than current standard care.
Working on the basis of the primary outcome measure results
alone, power calculations suggest that we would need a
sample size of > 400 participants per arm to be reasonably
confident of demonstrating a statistically significant difference
between participants on the waiting list and those in receipt of
PST.
So why was PST not more effective? One possibility is that
this intervention was not well matched with the sample
studied. The inclusion criteria were wide ranging; DEPVIT
included people with mild, moderate, and severe depressive
symptoms. A post hoc analysis suggested that those with
FIGURE 1. CONSORT flow diagram. *The delivery of PST in London was problematic. The original therapist resigned after having seen just 3
patients. It then took approximately 9 months to recruit and train a replacement therapist. After several visits to participants’ houses, the second
therapist reported feeling intimidated by some of the locations that were visited. A volunteer was found to accompany the therapist, but after two
more sessions the therapist resigned. It was too late in the trial to recruit a third therapist, so the decision was made to skip all future PST allocations
in the London area only. Hence the relatively low number of people assigned to PST.
TABLE 1. Baseline Participant Characteristics
Characteristic
Waiting List
(n ¼ 30)
Referral
(n ¼ 31)
PST
(n ¼ 24)
Gender, n (%)
Female 14 (46.7) 20 (64.5) 16 (66.7)
Male 16 (53.3) 11 (35.5) 8 (33.3)
Age
Mean years (SD) 72.3 (13.1) 67.1 (19.6) 71.8 (16.7)
Ethnicity, n (%)
Asian/Asian British 1 (3.3) 1 (3.2) 1 (4.2)
Black/Black British 4 (13.3) 10 (32.3) 1 (4.2)
Other ethnic group 0 (0.0) 1 (3.2) 0 (0.0)
White 25 (83.3) 19 (61.3) 22 (91.7)
Depressive symptoms
Baseline GDS-15 (SD) 10.1 (2.9) 9.5 (2.9) 9.1 (2.7)
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moderate to severe depressive symptoms at baseline (BDI-II
score ‡20) derived the greatest benefit from the active
treatment interventions. Hence, we may have observed larger
effects had we included only those with moderate to severe
symptoms at baseline.
Another possible explanation for the apparent lack of
effectiveness is that PST was not delivered as intended. The
fidelity check of audio recording suggests that PST delivery in
Wales was good and in London satisfactory to good. However,
in Wales it was not possible to deliver PST as per protocol in
30% of cases, and in London only one person allocated to PST
received it as described in the protocol. In Wales, the main
barrier to the per-protocol delivery of PST was participant
health. In London, a range of problems were experienced. The
first therapist was very experienced but resigned abruptly
citing unacceptable travel times to participants’ homes as
being an issue. The second therapist was less experienced and
found the delivery of PST challenging. She reported several
problems: some participants denied having problems and
therefore felt that PST was inappropriate; the emotional and
psychological issues could be overwhelming, and this made it
difficult to stick to the manualized intervention; communicat-
ing with people whose first language was not English was
problematic; and the therapist felt physically vulnerable in
some of the more deprived parts of South London. The second
therapist in London resigned 15 months after the trial started.
When it became clear that there was no possibility of
delivering PST as intended, the trial management group agreed
to close this arm of the trial in London.
Another explanation is that PST is just not very effective at
reducing depressive symptoms over longer follow-up periods
such as 6 months. In the original study by Rovner et al.,14
positive effects were reported at 2 months, but they were
substantially diminished by 6 months. That study did suggest
that booster treatments for all PST participants may be
beneficial. Had we modified the PST intervention in this way,
it is possible that more positive effects would have been
observed at 6 months.
Referring people to their physician was a pragmatic
intervention. It represented the most likely course of action
for those delivering rehabilitation services who discover that
one of their patients is depressed. At the conclusion of the trial,
we asked both the participants and their physicians about any
treatments received. Of the 36 referrals to the physicians, we
were unable to get a response from four physicians, and seven
said that they did not receive the referral letter. Clearly,
although the physician’s contact details were cross checked
with the practice website at the time the referral letter was
sent, communication breakdown between the referral center
and the physician is a distinct possibility. A phone call to check
TABLE 2. Primary and Secondary Outcomes
Outcome Measure Waiting List Referral PST
Depressive symptoms (BDI-II)
Mean baseline value (SD) 20.30 (10.33) 21.06 (7.61) 19.04 (10.62)
Change from baseline to 3 months (SD) 2.83 (10.38) 1.14 (8.49) 2.27 (5.81)
Change from baseline to 6 months (SD) 1.05 (8.85) 2.11 (7.60) 2.68 (7.94)
Screening positive at 6 months (GDS-15) 33.3% 38.5% 40.9%
Reading ability (LV VFQ-48)
Mean baseline value (SD) 1.20 (1.64) 1.02 (1.96) 0.83 (1.52)
Change from baseline to 3 months (SD) 0.17 (1.35) 0.05 (1.05) 0.10 (1.78)
Change from baseline to 6 months (SD) 0.09 (1.79) 0.08 (1.17) 0.09 (1.67)
Visual disability (seven-item NEI-VFQ)
Mean baseline value (SD) 0.90 (1.35) 0.43 (1.88) 0.52 (1.39)
Change from baseline to 3 months (SD) 0.25 (1.26) 0.19 (1.21) 0.13 (1.58)
Change from baseline to 6 months (SD) 0.34 (1.68) 0.22 (0.99) 0.35 (1.51)
Health status (EQ-5D)
Mean baseline value (SD) 0.47 (0.32) 0.43 (0.40) 0.43 (0.34)
Change from baseline to 3 months (SD) 0.02 (0.26) 0.03 (0.25) 0.07 (0.23)
Change from baseline to 6 months (SD) 0.02 (0.37) 0.34 (0.29) 0.07 (0.29)
Mean change in depressive symptoms at 3 and 6 months, proportion screening positive for depression at 6 months (GDS-15 score of 6 or more),
mean change in near reading ability (Near Vision subscale of the LV VFQ-48), and mean change in visual disability (seven-item NEI-VFQ). Both sets of
results are in logits, but the scales work in different directions. More positive scores on the LV VFQ 48 indicate greater ability. More positive scores
on the seven-item NEI-VFQ indicate greater disability; mean change in health status (EQ-5D).
TABLE 3. Physician’s Responses to Referral Letters
Action Taken by
Physician
Referral Letter 1,
% (n)
Referral Letter 2,
% (n)
Patient offered medication 12.9 (4) 60 (3)
Patient offered other 19.4 (6) 20 (1)
Patient offered medication
and other
12.9 (4)
Appointment with
physician but no
treatment
9.7 (3)
Offered appointment but
patient declined
3.2 (1) 20 (1)
No appointment 6.5 (2)
Did not receive letter 22.6 (7)
No response from
physician
12.9 (4)
Total 100 (31) 100 (5)
Two types of letters were sent to physicians during the trial.
Referral letter 1 was a carefully crafted letter and was the intervention
in the referral arm of the trial. The trial was stratified for severe/not
severe depressive symptoms (BDI-II score of 29 or more). For all of
those with severe depressive symptoms in any arm of the trial, referral
letter 2 was sent to the physician. This letter indicated that the patient
had severe depressive symptoms and requested a medication review.
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if the physician has received the referral letter would be
helpful in future studies.
It was not part of our analysis plan to determine what
happened to participants offered different interventions by the
physician, but it is perhaps noteworthy that 25% of those
referred to their physician were offered antidepressants. In
DEPVIT, depressive symptoms reduced by 13.2 (SD 6.3) points
on the BDI-II in the six people who were offered medication
and for whom data were available. Antidepressants are an
inexpensive, straightforward, and effective means of reducing
depressive symptoms. However, antidepressant use may be
associated with side effects such as insomnia, nausea,
increased weight gain, drowsiness, and agitation, and the rate
of relapse is relatively high.
Assuming that six sessions of PST would be offered to each
person on average, the overall costs of this intervention were
£1176 in Wales and £1296 in London. Total health and social
care service use costs during the 6-month trial period were
£400 lower in the PST arm of the trial than in the referral arm
and £482 lower in the PST arm than in the control arm.
However, although there is some suggestion that PST may
reduce costs, when the cost of the PST intervention is added,
the total cost of those in the PST arm was greater than in the
other arms of the trial.
The relatively high number of serious adverse events and
difficulties experienced making appointments to deliver PST
during the trial reflects the underlying state of health of the
participants. Participants were elderly, and comorbidity was
common. Interventions aimed at reducing depression in this
patient group, including those delivered via a stepped care
approach, should consider the practical difficulties associated
with intervention delivery. That some participants found
engaging with PST difficult because they claimed not to have
problems suggests that PST may not be appropriate for
everyone.
One important finding from the DEPVIT study was that the
prevalence of significant depressive symptoms in visual
rehabilitation clinics in Britain, at 43%, is among the highest
reported anywhere in the world. To put these findings in
perspective, other studies using the GDS-15 and the same cut-
off point have estimated that the prevalence of significant
depressive symptoms in people with a cancer diagnosis about
to start chemotherapy is 45%.27 We provide a description of
the prevalence data in another publication.28
Another significant observation from DEPVIT was that the
response rate was relatively low. That is, the main reason for
nonparticipation (n¼ 345) was refusal (n¼ 110; 32%). Refusal
is a common finding in other trials in this population. For
example, in the study by Rovner et al.,14 refusal was the main
reason (66%) for nonparticipation, and in the study by van der
Aa et al.29 only 914 of 3000 people invited to take part in the
study provided written consent. A better understanding of the
reasons why people are declining to take part may improve
recruitment rates to future trials and help people accept the
offer of treatment.
TABLE 4. Mean NHS and Local Authority Costs (£) Over 6 Months by Group
Health Care Service Use
Control
(n ¼ 27)*
GP Referral
(n ¼ 26)*
PST
(n ¼ 22)*
PST vs.
Control†
PST vs.
GP Referral†
Total primary care 192 (303) 169 (137) 214 (222) 22 (124 to 162) 45 (48 to 158)
GP consultations (surgery) 156 (271) 138 (129) 122 (119) 34 16
GP consultations (home) 10 (32) 4 (14) 49 (209) 39 45
Practice nurse consultations 25 (58) 24 (76) 43 (67) 18 19
Primary care antidepressant prescribing 1 (4) 3 (11) <1 (1) 1 3
Total community-based services 202 (761) 750 (1540) 415 (948) 213 (273 to 705) 335 (1066 to 349)
Community health workers‡ 124 (642) 353 (1302) 212 (908) 88 141
Mental health support services§ 0 (0) 71 (172) 20 (94) 20 51
Occupational therapy 3 (11) 2 (5) 4 (14) 1 2
Social services 21 (63) 74 (202) 51 (159) 30 23
Physical rehabilitation servicesjj 33 (116) 36 (94) 43 (136) 10 7
Other¶ 21 (30) 214 (930) 85 (235) 64 129
Total community-based services 202 (761) 750 (1540) 415 (948) 213 (273 to 705) 335 (1066 to 349)
Total local authority day care services 68 (351) 38 (194) 0 68 (248 to 89) 38 (144 to 134)
Total secondary care 982 (1826) 405 (622) 333 (583) 649 (1421 to 4) 72 (404 to 267)
Ophthalmology inpatient 0 (0) 0 (0) 75 (351) 75 75
Ophthalmology outpatient 138 (385) 110 (232) 103 (168) 35 7
Low vision assessment (LVA) 30 (49) 7 (24) 20 (47) 10 13
Inpatient (other) 601 (1824) 166 (601) 0 (0) 601 166
Outpatient (other) 202 (371) 107 (158) 128 (228) 74 21
Day case (other) 0 (0) 15 (76) 0 (0) 0 15
Accident and emergency 11 (41) 0 (0) 4 (20) 7 4
Therapy/counseling services 0 (0) 0 (0) 3 (12) 3 3
Total NHS and local authority service use cost 1444 (1941) 1362 (1842) 962 (1051) 482 (1334 to 323) 400 (1277 to 375)
Total service use cost and intervention cost 1444 (1941) 1362 (1842) 1775 (1044) 331 (554 to 1099) 413 (439 to 1193)
All costs rounded to nearest £.
* Reported as mean (SD).
† Reported as mean difference (bootstrapped 95% confidence interval, where appropriate).
‡ District nurse or health visitor.
§ Psychologist, therapist or counselor, or psychiatric nurse.
jj Physiotherapist or chiropodist.
¶ Dietician, optician, dentist, or meals on wheels.
Depression Treatments in People With Low Vision IOVS j August 2016 j Vol. 57 j No. 10 j 4252
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935593/ on 09/13/2016
The results of this trial add to those of other trials recently
published in this research area. For example, van der Aa et al.29
showed that a stepped care approach, which comprised
watchful waiting, guided self-help based on cognitive behav-
ioral therapy, problem-solving treatment, and referral to a
general practitioner significantly reduced the risk (relative risk
0.63) of a depressive dysthymic and/or anxiety disorder at 24
months.29 In another study, a relatively simple, low-intensity
psychological intervention known as BA, a treatment that
helps people recognize the link between action and mood,
often delivered in the person’s own home by an occupational
therapist during an 8-week period, was shown to halve the
incidence of depressive disorders in people with AMD at 4
months.15 In contrast, an 8-week, group-based low-vision self-
management program based on cognitive-behavioral approach-
es and social cognitive theory did not reduce depressive
symptoms at 6 months in people with low vision.30 However,
the people in that study were psychologically normal at
baseline. Another well designed clinical trial showed the anti-
depressant therapy, escitalopram, to be effective at reducing
depression in a small group of people with AMD and
depression at 4 months.31 Collectively, these studies suggest
that psychological and pharmacological interventions can be
effective in reducing depression in people with low vision.
However, comparisons are complicated because of differences
in the samples studied, the interventions tested, the follow-up
period, the instruments used to measure depression and
outcome measures, for example, change in depressive symp-
toms versus proportions with a depressive disorder. Table 5
summarizes the differences and outcomes of recent clinical
trials in this area. Overall, it appears that the psychological
interventions studied to date produce a small effect size (0.19
to 0.32) in people with low vision and depressive symptoms.
These modest findings are typical of those observed in other
chronic health conditions.10 The larger effect size (0.67)
observed in the small antidepressant trial is consistent with
results obtained for those prescribed antidepressants in
DEPVIT, but larger studies are needed.31
Taken together, these studies and our own experience of
trying to deliver psychological interventions to those with the
full spectrum of depressive symptoms (from mild to severe)
has led us to believe that screening this high-risk group is vital;
although PST may be helpful to some, it is not a panacea, and
there may be better low-intensity psychological interventions,
such as BA. It is unlikely that one intervention will suit
everyone, and hence patients should be offered a range of
treatment options tailored to their individual needs and the
severity of their depression. The stepped care delivery
platform can facilitate the delivery of individualized care and
provide long-term benefits.
The strengths of this study include publication of the study
protocol before recruitment began, an analysis based on
prespecified primary and secondary outcomes, relatively
successful masking of the outcome assessors, identification of
sources of bias, a minimal set of exclusion criteria, and the
large number of consecutive participants originally screened.
Limitations of this study included a relatively modest sample
size (n ¼ 85) and practical difficulties experienced trying to
deliver PST per protocol.
CONCLUSIONS
Our study suggests that PST and referring people to their
physician are more effective than doing nothing for the
treatment of depression in people with low vision, but the
results were not compelling. Those with moderate to severe
depressive symptoms benefited most from the interventions at
a moderate cost.
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